On September 8 2020, nine CEOs of global vaccine developers of COVID-19 vaccine candidates published a pledge to uphold the integrity of the scientific and regulatory process as they work towards approvals of the first COVID-19 vaccines.

Vaccines Europe fully supports this pledge, which is aligned with our ongoing commitment to the safety of COVID-19 vaccines.

In response to the devastating human and economic cost of the COVID-19 crisis, our members are working in collaboration with academic institutions, European and international organisations as well as across the life sciences sector to find vaccines that can stop the coronavirus pandemic in its tracks.

These vaccines will be assessed by the European Medicines Agency (EMA) and other regulators around the world. They will only be approved based on rigorous and objective scientific review of safety and efficacy data based on large-scale, high quality, randomised and observer-blinded clinical trials.

The health and safety of people receiving any vaccine is our first priority, and that applies equally to recipients of a COVID-19 vaccine. Underlining our commitment to the safety, efficacy and quality of COVID-19 vaccines:

- We commit to always make the safety and well-being of vaccinated individuals our number one priority
- We commit to the highest scientific and ethical standards in conducting clinical trials for COVID-19 vaccines and the rigor of manufacturing processes
- We will only submit COVID-19 vaccines for approval after demonstrating safety and efficacy data through phase 3 clinical studies that are designed and conducted to meet the requirements of expert regulatory authorities such as the EMA
- We will work to ensure a sufficient supply and range of vaccine options, including those suitable for global access